Alpha-Interferon and Immune Hemolytic Anemia

Letters and Corrections1 August 1986Alpha-Interferon and Immune Hemolytic AnemiaLUKE P. AKARD, M.D., RONALD HOFFMAN, M.D., LAURENCE ELIAS, M.D., JOSEPH H. SAIERS, M.D.LUKE P. AKARD, M.D., RONALD HOFFMAN, M.D., LAURENCE ELIAS, M.D., JOSEPH H. SAIERS, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-2-306_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Interferons have been shown to cause regression in several malignancies (1-3). Although the proper role of interferons in the treatment of cancer has yet to be defined, they are generally regarded as relatively nontoxic. We report here two cases of apparent immune-mediated erythrocyte destruction occurring during interferon treatment.Patient 1: A 56-year-old white man with metastatic renal cell carcinoma was treated with vinblastine, 5 mg/m2body surface area on day 1 once monthly, combined with alpha-2-interferon, 3 million U/m2on day 1, 5 million U/m2on day 2, and 10 million U/m2on days 3 through 5,...References1. SHERWINKNOSTFEIN SJS. A multiple-dose phase 1 trial of recombinant leukocyte interferon in cancer patients. JAMA. 1982;248:2461-6. CrossrefMedlineGoogle Scholar2. QUESADAHAWKINSHORNING JMS. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma and multiple myeloma. Am J Med. 1984;77:427. CrossrefMedlineGoogle Scholar3. FOONSHERWINABRAMS KSP. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte alpha interferon. N Engl J Med. 1984;311:1148-52. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: LUKE P. AKARD, M.D.; RONALD HOFFMAN, M.D.; LAURENCE ELIAS, M.D.; JOSEPH H. SAIERS, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInterferon alfaDrugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007CYTOKINES AND CYTOKINE MODULATORSANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONSAutoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosisAn update on drug-induced immune hemolytic anemiaInterferon-induced sarcoidosisInterferon alfaDrug-Induced Immune Hemolytic AnemiaInterferon alpha et auto-immunitéSystemic sclerosis after interferon-alfa therapy for myeloproliferative disordersEssential Thrombocythemia (ET): Moving from Palliation to CureInfection par le virus de l'hépatite C et pathologies thyroïdiennesThrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemiaHemolytic Anemia Secondary to Alpha-Interferon Treatment in a Patient With Chronic C HepatitisAntiviral Chemotherapy for Viral HepatitisGranulomatous dermatitis with focal sarcoidal features associated with recombinant interferon β-1b injectionsLocal Cutaneous Necrotizing Lesions Associated with Interferon InjectionsAlpha-interferon-induced arthritis: clinical presentation, treatment, and preventionNo eidence for increased frequency of autoantibodies during interferon-β lb treatment of multiple sclerosisInterferontherapie und AutoimmunitätNew drugs in essential thrombocythemia and polycythemia veraAdverse Effects of Interferon TreatmentDevelopment of Sjögren's syndrome during treatment with recombinant human interferon-alpha-2b for chronic hepatitis CSide effects of high-dose interferon therapy for chronic hepatitis CHemolytic anemia and cancerHemolytic anemia provoked by recombinant alpha-interferonImmunological Adverse Effects of Interferon TreatmentThe role of cytokines in the immunopathogenesis of lupusThe Role of α-Interferon in Essential Thrombocythaemia, Polycythaemia Vera and Myelofibrosis with Myeloid Metaplasia (MMM): A Concise UpdateDrugs Recently Associated With Lupus SyndromesRole of the Biologics in AutoimmunityClinical and Immunohistochemical Studies of Skin Eruptions: Relationship to Administration of Interferon-αAcquired factor VIII inhibitor associated with chronic interferon-alpha therapy in a patient with haemophilia AInduction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferonHypothyroidism and arthritis during interferon therapyAutoimmunity during alpha-interferon therapy for chronic hepatitis CMaladies auto-immunes et traitement par l'IFN-α: revue de la littérature à propos d'un cas d'hyperthyroïdieLupus-like autoimmune disease induced by interferon therapy for myeloproliferative disordersA case of arthropathy and hypothyroidism during recombinant alpha-interferon therapyInterferon-α2b in the treatment of follicular lymphoma: Preliminary results of a trial in progressInterferon-α2b in the treatment of follicular lymphoma: Preliminary results of a trial in progressExacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapyImmunisation rates in general practiceThe truth about juniors' hoursDeath after flumazepil.Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides.A case of fatalPemphigus Vulgaris in association with beta interferon and interleukin-2 therapyCytokine-Based Therapy for Cancer 1 August 1986Volume 105, Issue 2Page: 306-306KeywordsBody surface areaCancer treatmentHemolytic anemiaInterferonsPatientsRenal cell carcinoma ePublished: 1 December 2008 Issue Published: 1 August 1986 PDF downloadLoading ...